$(document).ready(function() {window.print();});>
From the NAPWA website at http://www.napwa.org.au/pl/2010/06/new-nrti-no-more

New NRTI no more

Created 11 Jun 2010 - 11:42am

The shelving of apricitabine does not come as a surprise in the competitive HIV sector, in which market growth is increasingly being driven by fixed-dose combinations (FDCs) such as Atripla which offer improved patient convenience.

Furthermore, apricitabine’s twice-daily administration impedes its potential for combination with other antiretroviral [1]A medication or other substance which is active against retroviruses such as HIV. drugs and limits its scope for use in FDCs.

This is reflected in the fact that there are currently no other NRTIs in late-stage development for HIV.

Information on the NAPWA website is provided subject to conditions of use that can be view at napwa.org.au. Visit the website for updated versions of this information.

Links:
[1] http://www.napwa.org.au/glossary/term/122